Oropharyngeal squamous cell carcinoma (OPSCC) is an increasingly common cancer of the upper aerodigestive tract, and includes cancers arising from the tonsils, base of tongue (BOT), soft palate, and lateral and posterior pharyngeal walls. Although traditionally associated with heavy tobacco and alcohol consumption, it is estimated that ∼60--70% of incident OPSCC cases are attributable to human papillomavirus (HPV) ([@bib12]; [@bib3]; [@bib8]). A rise in HPV-positive OPSCC has occurred since the 1980s in the United States that has been attributed to changing sexual practices beginning in the 1960s ([@bib16]; [@bib6]). The HPV epidemic has changed the demographic characteristics of OPSCC patients considerably. Patients with HPV-positive OPSCC are generally younger than those with HPV-negative OPSCC and are often never smokers. An association with increased number of sexual partners and earlier sexual debut has also been demonstrated ([@bib10]; [@bib22]). The HPV-positive OPSCC is an increasingly significant public health problem; it is projected that by 2020 HPV-positive OPSCC will overtake cervical cancer as the most common HPV-related malignancy in the United States ([@bib8]).

Tonsillectomy is a commonly performed surgical procedure that involves removal of the palatine tonsils, most often in children for hypertrophic tonsils, chronic infection, or obstructive sleep apnoea ([@bib13]). The rates of tonsillectomy in the United States have changed significantly over the past several decades. [@bib31]) and others ([@bib13]; [@bib15]) demonstrated a sharp decline in tonsillectomy rates beginning in the late 1970s. It is well established that an increase in HPV-related OPSCC began to increase in the 1990s ([@bib7], [@bib8], [@bib6]). The association between tonsillectomy and risk of OPSCC has not been extensively investigated. A recent study of the Danish Cancer Registry suggests a reduction in risk of tonsil cancer in patients with a previous history of tonsillectomy ([@bib17]). The purpose of this study is to examine the association between previous tonsillectomy and risk of OPSCC using a large North Carolina population-based head and neck cancer case--control study. We hypothesise that previous tonsillectomy is associated with a decreased risk of tonsil cancer with no impact on the risk of BOT cancer.

Materials and methods
=====================

Study population
----------------

The Carolina Head and Neck Cancer Study (CHANCE) is a population-based case--control study of squamous cell carcinoma of the head and neck ([@bib14]). Case ascertainment utilised rapid ascertainment of newly diagnosed cancer cases through the North Carolina Central Cancer Registry. Cases were diagnosed with primary squamous cell carcinoma of the oral cavity, pharynx, and larynx between 1 January 2002 and 28 February 2006, were aged 20 to 80 years at diagnosis, and resided in a 46-county region in central North Carolina. Benign tumours, carcinomas *in situ*, papillary carcinomas, and adenocarcinomas were excluded. Controls were identified through the North Carolina Department of Motor Vehicle records and were frequency matched with cases on age, race, and sex.

The Carolina Head and Neck Cancer Study enrolled 1368 total cases; however, as we are only interested in OPSCC, we restricted the tumour site to only the oropharynx (*N*=372). Race other than European American and African American were excluded from the analysis because of sparse numbers (*N*=11). As we are interested specifically in the OPSCC subsites, cases were classified into two categories: (1) BOT: C01.9 and C02.4 and (2) tonsil: C09.0, C09.1, C09.8, and C09.9. We excluded OPSCC of the vallecular (C10.0; *N*=10), soft palate (C05.1, C05.2; *N*=23), and unspecified subsites (C10.8 and C10.9; *N*=23) because of small sample size. The HPV typing and p16 immunohistochemistry was performed on all cases of oropharyngeal tumours for which tumour blocks were available (*N*=213). All European-American and African-American controls were included in the analysis (*N*=1378). This study was approved by the institutional review board at the University of North Carolina at Chapel Hill.

Questionnaire and clinical assessment
-------------------------------------

Demographic, lifestyle, oral health, diet, and other risk factor information were collected using a structured questionnaire during an in-home visit conducted by trained nurse-interviewers. The median time between diagnosis and in-home interview was 4 months (interquartile range: 3--6 months). Two questions addressed a history of previous tonsillectomy, including, 'Were your tonsils removed?\' and 'How old were you when tonsils removed?\' For subjects who were unable to recall the exact age of tonsillectomy, the subject was able to answer child, teenager, or adult. Age at tonsillectomy was defined as before 13 years of age (child) and after 13 years of age (teenager and adult). The CHANCE questionnaire focussed on lifestyle and medical and family history risk factors. Interviewers did not collect information on tonsillectomy performed as part of the diagnostic workup or OPSCC therapy. Confounders to be adjusted for in statistical models were selected *a priori* based on their potential association with risk of OPSCC and tonsillectomy. Confounders obtained from the questionnaire included: age race, sex, smoking (\<10 pack-years and ⩾10 pack-years), insurance status (private, Medicare/Medicaid, none, and other), education (some high school, completed high school, some college and above), alcohol (1 drink or less per week/\>1 drink a week), and number of sexual partners (0--1, 2--5, 6--14, and 14+).

p16 immunohistochemistry and HPV typing
---------------------------------------

Immunohistochemistry (IHC) for p16 was performed according to the protocol provided with the CINtec Histology p16^INK4a^ Kit (Ref 9511, mtm laboratories, Heidelberg, Germany) for the qualitative detection of the p16 antigen on slides prepared from formalin-fixed, paraffin-embedded biopsies. The p16 IHC scoring method used in this study was developed based on the methodology by [@bib26]), where expression was scored based on the percentage (0%=0, 1--10%=1, 11--50%=2, 51--80%=3, and 81--100%=4) and intensity (none=0, weak=1, moderate=2, and strong=3) of nuclear or cytoplasmic staining, and a combined score of ⩾4 was considered positive for p16 overexpression. This algorithm has been previously published in a study from the International Agency for Research on Cancer (IARC) ([@bib2]), and has been compared with other p16 scoring methods with similar results ([@bib37]; [@bib35]; [@bib34]). The HPV typing was determined through DNA extraction and genotyping by Luminex-based multiplex PCR (TS-E7-MPG, IARC, Lyon, France) ([@bib20]; [@bib32], [@bib33]). Tumours were classified as HPV-positive if they were positive for HPV16 or HPV18.

Statistical analysis
--------------------

Differences in descriptive statistics by OPSCC subsite were estimated using the *χ*^2^ test and Fisher\'s exact test when cells were sparse. Unconditional logistic regression was used to calculate odds ratio (OR) adjusted with the confounders and matching factors: age, race, and gender. Subsite-specific adjusted ORs were calculated with unconditional multinomial logistic regression. To further explore the role of HPV, conditional logistic regression was used to calculate HPV/p16 status and subsite stratified ORs based on the matching factors, including age (defined in 7 categories), race (White/Black), and sex. All statistical analyses were implemented using SAS 9.3 (SAS Institute, Cary, NC, USA).

Results
=======

The study population comprised 1378 controls and 361 OPSCC cases, including 108 BOT and 198 tonsil cancer cases. [Table 1](#tbl1){ref-type="table"} shows the demographic, risk factor, and tumour characteristics of the controls and cases by subsite. Cases and controls differed with respect to sex, age, tobacco pack-years, education level, insurance status, age at tonsillectomy, and rates of previous tonsillectomy (40% *vs* 26.3% in controls and cases, respectively, *P*\<0.001). Among study subjects with a history of tonsillectomy, 2 (2.5%) cases and 6 (1.1%) controls underwent the procedure within 10 years of enrolment in the study. No significant differences were noted between BOT and tonsil cancer cases with respect to age, sex, race, education and insurance status, p16 tumour status, and HPV tumour status. A history of previous tonsillectomy differed significant between tonsil (11.3%) and BOT (53.3%) cancer cases (*P*\<0.0001). The BOT cancer cases with a history of tonsillectomy were significantly more likely to have undergone the procedure in childhood (92.9% among BOT cases and 68.2% among tonsil cancer cases, *P*\<0.001).

[Table 2](#tbl2){ref-type="table"} presents the results of the logistic regression model for selected factors and the odds of OPSCC by subsite. A greater number of sexual partners and \>10 pack-year tobacco history were associated with an increased odds of all OPSCC, tonsil, and BOT cancers compared with controls. When all OPSCC cases were evaluated, there was a significantly decreased odds of cancer associated with previous tonsillectomy (OR=0.63, 95% confidence interval (CI) 0.47--0.85, *P*=0.003). When OPSCC subsite was considered, previous tonsillectomy was associated with a nearly two-fold increased odds of BOT cancer (OR=1.95, 95% CI 1.25--3.06, *P*=0.003) and a large decrease in the odds of tonsil cancer (OR=0.22, 95% CI 0.13--0.36, *P*\<0.001). We found tonsillectomy not associated with sites of head and neck cancer not commonly associated with HPV ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). We then considered whether age at tonsillectomy affected the risk of OPSCC by subsite ([Table 3](#tbl3){ref-type="table"}). Childhood tonsillectomy (age \<13 years) was strongly associated with increased odds of BOT cancer (adjusted OR=2.46, 95% CI 1.55--3.92, *P*\<0.001), and no association was noted with tonsillectomy after age 13 years (OR=0.33, 95% CI 0.08--1.42, *P*=0.138). Tonsillectomy before age 13 years (OR=0.19, 95% CI 0.10--0.33, *P*\<0.001) and after age 13 years (OR=0.32, 95% CI 0.14--01.00, *P*=0.017) was associated with a significantly decreased odds of tonsil cancer.

In an exploratory analysis including cases with available tumour tissue, we then examined the odds of tonsil and BOT cancer by HPV and by p16 status ([Table 4](#tbl4){ref-type="table"}). Tonsillectomy was associated with a decreased odds of HPV-positive tonsil cancer (OR=0.17, 95% CI 0.08--0.34, *P*\<0.001) and a decreased but imprecise odds of HPV-negative tonsil cancer (OR=0.66, 95% CI 0.24--1.81, *P*=0.415). Conversely, tonsillectomy was associated with an increased odds of HPV-positive BOT cancer (OR=2.46, 95% CI 1.22--4.95, *P*=0.012) and a weak and imprecise increase in odds of HPV-negative BOT cancer (OR=1.24, 95% CI 0.46--3.31, *P*=0.671). Tonsillectomy was also associated with a significantly increased odds of p16-positive BOT cancer (OR=2.24, 95% CI 1.16--4.35, *P*=0.017) and only a weak increase in odds of p16-negative BOT cancer (OR=1.21, 95% CI 0.43--3.36, *P*=0.716). Tonsillectomy was associated with decreased odds of p16-positive tonsil cancer (OR=0.14, 95% CI 0.07--0.31, *P*\<0.001). A decrease of p16-negative tonsil cancer was also seen, but the OR had a very wide CI (OR=0.81, 95% CI 0.31--2.10, *P*=0.670). Finally, similar results were noted between previous tonsillectomy, HPV+/p16+ BOT cancer (OR=2.18, 95% CI 1.1--4.4), and HPV+/p16+ tonsil cancer (OR=0.16, 95% CI 0.08--0.37).

Discussion
==========

This population-based case--control study explores the association between previous tonsillectomy and odds of OPSCC. We found that previous tonsillectomy was associated with a significantly decreased odds of OPSCC overall that was driven by a sharp and expected decrease in tonsil cancer specifically. These data suggest that tonsillectomy results in a reduction of oropharyngeal lymphoid tissue susceptible to malignant transformation ([@bib17]). An unexpected finding from this analysis was the positive association between odds of BOT cancer and previous tonsillectomy. Although having a tonsillectomy is inversely associated with odds of tonsil cancer, our data suggest that tonsillectomy may be associated with an increased odds of BOT cancer. One possible explanation is lingual tonsillar hypertrophy in patients with a history of tonsillectomy, resulting in increased lymphoid tissue in the BOT. Enlargement of the lingual tonsils has been noted in up to one-third of paediatric patients undergoing adenotonsillectomy ([@bib18]), and is a recognised cause of persistent sleep apnoea and airway obstruction in this population ([@bib24]; [@bib21]; [@bib9]; [@bib25]; [@bib4]; [@bib1]; [@bib19]). Our data suggest that the odds of BOT cancer is strongly increased in patients undergoing tonsillectomy as children (age \<13 years) compared with adolescents and adults (age \>13 years). The difference in odds of BOT cancer by age of tonsillectomy further supports the possible association between lingual tonsillar hypertrophy and increased susceptibility to BOT cancer. The most common indication for tonsillectomy in children is obstruction secondary to adenotonsillar hypertrophy ([@bib36]; [@bib29]). In contrast, the most common indication for tonsillectomy in adults is chronic or recurrent tonsillitis ([@bib23]).

An exploratory analysis of the association between tonsillectomy, tonsil, and BOT cancer, and HPV status yielded interesting results. When both subsite and HPV status were considered, we demonstrated that tonsillectomy was associated with a significantly decreased odds of HPV-positive tonsil cancer and a decreased but insignificant odds of HPV-negative tonsil cancer. The weaker association between tonsillectomy and HPV-negative tonsil cancer may result from susceptibility of nonlymphoid tissues of the tonsillar region (anterior tonsillar pillars, posterior tonsillar pillars, and tonsillar fossa) to HPV-negative, tobacco-associated cancer even in the setting of previous tonsillectomy. Ultimately, the decrease in odds of tonsil cancer in patients with a history of tonsillectomy is expected and logical. The association by HPV status should be explored further in larger studies. With respect of HPV-positive and HPV-negative BOT cancer, our data suggest that the association between tonsillectomy and an increased odds of BOT cancer is strongest for HPV-positive tumours. The reason for this difference by HPV status remains unclear and warrants further investigation, and may reflect a relatively small sample size of HPV-negative tumours.

Recently, the possibility of prophylactic tonsillectomy as a method of secondary OPSCC prevention has been considered ([@bib5]; [@bib17]). Although we demonstrate a reduction in overall risk of OPSCC cancer associated with tonsillectomy, our study was not designed to address this question. It is important to consider that despite being a commonly performed surgery, the morbidity of tonsillectomy is not insignificant ([@bib30]; [@bib38], [@bib39]). Furthermore, as demonstrated by [@bib17]), the relative rarity of OPSCC further precludes tonsillectomy from being an effective method of prevention. Vaccination against high-risk HPV types has the potential to serve as a safer and more effective method of primary prevention of OPSCC than tonsillectomy ([@bib11]). Nonetheless, when considered along with other covariates such as sexual history, smoking status, and age, a history of tonsillectomy may play a role in risk stratification ([@bib5]; [@bib17]).

This study has several limitations, many of which are inherent to the case--control study design. The use of self-reported tonsillectomy questionnaire data presents the possibility of recall bias and differential misclassification by disease status. However, recall of tonsillectomy would be very long for both the cases and the controls and at the time of recruitment. Because most tonsillectomies among cases and controls occurred at a very young age, medical record abstract is not feasible. Two previous studies have examined the accuracy of tonsillectomy recall, demonstrating sensitivity and specificity of recall were 92.7% and 77.5% in one study and 78.9% and 80.1% in the other, respectively ([@bib27]; [@bib28]). Using the false discovery and false omission rates from these studies, we conducted a sensitivity analysis (methods in [Supplementary Material](#sup1){ref-type="supplementary-material"}) and found that our estimates for tonsillectomy and tonsil cancer are very stable to changes in recall ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). However, for BOT cancer as differential recall between cases and controls widens, the estimates move closer to null and eventually crosses the null ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). It is unlikely that recall was that dramatically different between the cases and the controls. Another important limitation of this study is that tumour tissue was not available for all OPSCC samples in this cohort, limiting our analysis including HPV to a secondary, exploratory analysis. Tonsil cancer samples were more likely to be typed and this could potentially lead to selection bias affecting our analysis by HPV and p16 status. However, subjects with available HPV status and those without were similar with respect to demographics, age, smoking history, number of sexual partners, and stage at presentation, suggesting that HPV status would be similar between those typed and nontyped. Possible selection bias would not affect our overall results with respect to risk of tonsil *vs* BOT cancer, or our results incorporating age at tonsillectomy, as all cases were included in these analyses. Furthermore, our results involving HPV and p16 typing were stratified by subsite, thus diminishing the potential impact of any selection bias. A final limitation of this study is that some of the comparisons were based on small numbers and ORs were associated with wide CIs. Despite these limitations, this study offers important insight into the association between previous tonsillectomy and risk of OPSCC.

The major strengths of this study include a relatively large number of diverse patients and a population-based, case--control study design. The availability of detailed smoking, HPV tumour status, sexual history, socioeconomic status, and other demographic covariates, as well as a frequency-matched control group, add to the validity of our findings. Data on age of tonsillectomy allowed us to demonstrate that the majority of cases and controls underwent tonsillectomy as children and presumably for reasons other than suspected oropharyngeal cancer. A very small fraction of cases and controls underwent tonsillectomy within 10 years of OPSCC diagnosis or enrolment in CHANCE, respectively. When a sensitivity analysis was conducted excluding subjects with a history of tonsillectomy within 10 years of enrolment in CHANCE, there were no significant differences in the study findings.

In conclusion, this population-based case--control study demonstrates that previous tonsillectomy is associated with a decreased odds of tonsil cancer and an increased odds of BOT cancer. Although these finding do not necessarily support the role of tonsillectomy as primary prevention, tonsillectomy should be considered when evaluating risk for OPSCC.
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###### 

Click here for additional data file.

###### Descriptive statistics and comparisons between controls and all oropharynx cases and comparisons by subsite

                                                  **Control (*****N***=**1378)**   **All oropharynx (*****N***=**361)**            **Base of tongue (*****N***=**108)**   **Tonsil (*****N***=**198)**    
  ---------------------------------------------- -------------------------------- -------------------------------------- --------- -------------------------------------- ------------------------------ ---------
  **Tonsillectomy**                                                                                                                                                                                      
  No                                                        815 (60%)                          260 (73.7%)               \<0.001   49 (46.7%)                             173 (88.7%)                    \<0.001
  Yes                                                       544 (40%)                           93 (26.3%)                         56 (53.3%)                             22 (11.3%)                      
  Missing                                                       19                                  8                              3                                      3                               
  **Race**                                                                                                                                                                                               
  White                                                    1114 (80.8%)                        277 (76.7%)               0.082     88 (81.5%)                             153 (77.3%)                    0.390
  Black                                                    264 (19.2%)                          84 (23.3%)                         20 (18.5%)                             45 (22.7%)                      
  **Education**                                                                                                                                                                                          
  Some High School                                         217 (15.7%)                          98 (27.1%)               \<0.001   22 (20.4%)                             55 (27.8%)                     0.192
  Completed High School                                    332 (24.1%)                          97 (26.9%)                         28 (25.9%)                             57 (28.8%)                      
  Some College and above                                   829 (60.2%)                          166 (46%)                          58 (53.7%)                             86 (43.4%)                      
  **Tobacco pack-years**                                                                                                                                                                                 
  ⩽10 Pack-years                                           765 (55.8%)                         112 (31.4%)               \<0.001   36 (33.3%)                             63 (32%)                       0.809
  \>10 Pack-years                                          606 (44.2%)                         245 (68.6%)                         72 (66.7%)                             134 (68%)                       
  Missing                                                       7                                   4                                                                     1                               
  **Sex**                                                                                                                                                                                                
  Male                                                     960 (69.7%)                         299 (82.8%)               \<0.001   95 (88%)                               165 (83.3%)                    0.279
  Female                                                   418 (30.3%)                          62 (17.2%)                         13 (12%)                               33 (16.7%)                      
  **Insurance**                                                                                                                                                                                          
  Private                                                  556 (40.4%)                         181 (50.3%)               \<0.001   59 (54.6%)                             104 (52.5%)                    0.980
  Medicaid/Medicare                                        437 (31.7%)                          93 (25.8%)                         24 (22.2%)                             44 (22.2%)                      
  None                                                      76 (5.5%)                           40 (11.1%)                         11 (10.2%)                             22 (11.1%)                      
  Other                                                    308 (22.4%)                          46 (12.8%)                         14 (13%)                               28 (14.1%)                      
  Missing                                                       1                                   1                                                                                                     
  **Tumour p16 status**                                                                                                                                                                                  
  Positive                                                      --                              84 (34.0%)               --        46 (65.7%)                             99 (69.2%)                     0.6051
  Negative                                                      --                             163 (66.0%)                         24 (34.3%)                             44 (30.8%)                      
  Missing                                                      1378                                125                             38                                     55                              
  **Tumour human papillomavirus (HPV) status**                                                                                                                                                           
  Positive                                                      --                             168 (67.7%)               --        43 (60.6%)                             104 (72.7%)                    0.0708
  Negative                                                      --                              80 (32.3%)                         28 (39.4%)                             39 (27.3%)                      
  Missing                                                      1378                                124                             37                                     55                              
  **Age**                                                                                                                                                                                                
  \<50 Years                                               156 (11.3%)                          86 (23.8%)               \<0.001   18 (16.7%)                             52 (26.3%)                     0.397
  50--54 Years                                             161 (11.7%)                          84 (23.3%)                         29 (26.9%)                             50 (25.3%)                      
  55--59 Years                                              207 (15%)                           69 (19.1%)                         21 (19.4%)                             42 (21.2%)                      
  60--64 Years                                             205 (14.9%)                          53 (14.7%)                         17 (15.7%)                             22 (11.1%)                      
  65--69 Years                                             247 (17.9%)                          35 (9.7%)                          10 (9.3%)                              18 (9.1%)                       
  70--74 Years                                             231 (16.8%)                          25 (6.9%)                          10 (9.3%)                              10 (5.1%)                       
  \>75 Years                                               171 (12.4%)                           9 (2.5%)                          3 (2.8%)                               4 (2%)                          
  **Age at tonsillectomy**                                                                                                                                                                               
  Child                                                    417 (77.1%)                          76 (82.6%)               \<0.001   52 (92.9%)                             15 (68.2%)                     \<0.001
  Teenager                                                  37 (6.8%)                            5 (5.4%)                          1 (1.8%)                               3 (13.6%)                       
  Adult                                                     87 (16.1%)                          11 (12.0%)                         3 (5.4%)                               4 (18.2%)                       
  No tonsillectomy                                             815                                 260                             49                                     173                             
  Missing                                                       22                                  9                              3                                      3                               

###### Adjusted odds ratio for all oropharyngeal cancer cases and by subsite compared with controls[a](#t2-fn2){ref-type="fn"}

                                   **Oropharyngeal cancer**  **Base of tongue cancer**    **Tonsil cancer**                                 
  ------------------------------- -------------------------- --------------------------- ------------------- --------- -------------------- ---------
  **Tonsillectomy**                                                                                                                         
  No                                         Ref             --                                  Ref         --                Ref          --
  Yes                                 0.63 (0.47--0.85)      0.003                        1.95 (1.25--3.06)  0.003      0.22 (0.13--0.36)   \<0.001
  **Number of sexual partners**                                                                                                             
  0--1                                       Ref             --                                  Ref         --                Ref          --
  2--5                                2.44 (1.40--4.27)      0.002                        2.1 (0.84--5.21)   0.110       3.44 (1.5--7.91)   0.004
  6--14                               3.81 (2.19--6.60)      \<0.001                      3.42 (1.42--8.27)  0.006       5.69 (2.49--13)    \<0.001
  14+                                 4.65 (2.65--8.18)      \<0.001                      3.75 (1.52--9.21)  0.004      7.73 (3.33--17.96)  \<0.001
  **Education**                                                                                                                             
  Some High School                           Ref             --                                  Ref         --                Ref          --
  Completed High School               0.61 (0.41--0.91)      --0.015                      0.67 (0.34--1.32)  --0.248    0.59 (0.36--0.97)   --0.037
  Some College and above              0.45 (0.31--0.66)      \<0.001                      0.54 (0.29--1.03)  0.061       0.4 (0.25--0.64)   \<0.001
  **Pack-years**                                                                                                                            
  \<10 Pack-years                            Ref             --                                  Ref         --                Ref          --
  ⩾10 Pack-years                       2.2 (1.62--2.97)      \<0.001                      1.91 (1.18--3.09)  0.009       2.23 (1.5--3.32)   \<0.001
  **Insurance**                                                                                                                             
  Private                                    Ref             --                                  Ref         --                Ref          --
  Medicaid/Medicare                   0.84 (0.57--1.25)      0.393                        0.59 (0.3--1.13)   0.113      0.78 (0.46--1.31)   0.341
  None                                0.92 (0.55--1.53)      0.743                        0.86 (0.37--1.98)  0.717      0.93 (0.51--1.72)   0.823
  Other                                0.7 (0.45--1.09)      0.112                         0.6 (0.3--1.19)   0.1434     0.81 (0.47--1.41)   0.464
  **Alcohol**                                                                                                                               
  ⩽1 Drink per week                          Ref             --                                  Ref         --                Ref          --
  \>1 Drink per week                  1.72 (1.16--2.56)      0.007                        1.23 (0.67--2.27)  0.503      1.67 (0.98--2.84)   0.058

Abbreviations: CI=confidence interval; OR=odds ratio; Ref=reference value.

Odds ratios are all mutually adjusted for in addition to matching factors (age, race, and gender).

###### Adjusted odds ratios for age at tonsillectomy by oropharyngeal subsite compared with controls[a](#t3-fn2){ref-type="fn"}

                                   **Base of tongue**   **Tonsil**                      
  ------------------------------- -------------------- ------------ ------------------- ---------
  **Age at tonsillectomy**                                                              
  No tonsillectomy                        Ref               --              Ref            --
  \<13 years                       2.46 (1.55--3.92)     \<0.001     0.19 (0.1--0.34)    \<0.001
  ⩾13 years                        0.33 (0.08--1.42)      0.138      0.32 (0.14--0.72)    0.006
  **Number of sexual partners**                                                         
  0--1                                    Ref               --              Ref            --
  2--5                             2.22 (0.89--5.54)      0.087      3.46 (1.5--7.95)     0.004
  6--14                             3.5 (1.45--8.45)      0.005      5.71 (2.5--13.05)   \<0.001
  14+                              3.96 (1.61--9.73)      0.003      7.8 (3.36--18.15)   \<0.001
  **Education**                                                                         
  Some High School                        Ref               --              Ref            --
  Completed High School            0.66 (0.34--1.31)      0.234      0.59 (0.36--0.96)    0.034
  Some College and above            0.5 (0.26--0.94)      0.031      0.4 (0.25--0.64)    \<0.001
  **Pack-years**                                                                        
  \<10 Pack-years                         Ref               --              Ref            --
  ⩾10 Pack-years                   1.88 (1.16--3.04)      0.011      1.66 (0.98--2.83)    0.061
  **Insurance**                                                                         
  Private                                 Ref               --              Ref            --
  Medicaid/Medicare                0.59 (0.31--1.15)      0.120      0.78 (0.47--1.32)    0.360
  None                             0.81 (0.35--1.87)      0.624       0.92 (0.5--1.7)     0.797
  Other                             0.59 (0.3--1.18)      0.138      0.81 (0.47--1.41)    0.457
  **Alcohol**                                                                           
  ⩽1 drink per week                       Ref               --              Ref            --
  \>1 drink per week                1.30 (0.7--2.39)      0.402      2.24 (1.51--3.32)   \<0.001

Abbreviations: CI=confidence interval; OR=odds ratio; Ref=reference value.

Odds ratios are all mutually adjusted for in addition to matching factors (age, race, and gender).

###### Adjusted odds ratio for tonsillectomy and oropharyngeal subsite and HPV/p16 status compared with controls[a](#t4-fn2){ref-type="fn"}

                        **Base of tongue/HPV+**   **Base of tongue/HPV**−   **Tonsil/HPV+**    **Tonsil/HPV**−                                                                                               
  -------------------- ------------------------- ------------------------- ----------------- ------------------- ------- ------------ ------------------- --------- ------------ ------------------- ------- ------------
  **Tonsil removed**                                                                                                                                                                                         
  No                              Ref                       --                17 (65.4%)             Ref           --     21 (72.4%)          Ref            --      99 (79.2%)          Ref           --     32 (82.1%)
  Yes                      2.46 (1.22--4.95)               0.012               9 (34.6%)      1.24 (0.46--3.31)   0.671   8 (27.6%)    0.17 (0.08--0.34)   \<0.001   26 (20.8%)   0.66 (0.24--1.81)   0.415   7 (17.9%)

                        **Base of tongue/p16+**   **Base of tongue/p16**−   **Tonsil/p16+**    **Tonsil/p16**−                                                                                              
  -------------------- ------------------------- ------------------------- ----------------- ------------------- ------- ------------ ------------------- --------- ------------ ------------------- ------ ------------
  **Tonsil removed**                                                                                                                                                                                        
  No                              Ref                       --                21 (44.7%)             Ref           --     16 (66.7%)          Ref            --      95 (92.2%)          Ref           --    36 (81.8%)
  Yes                      2.24 (1.16--4.35)               0.017              26 (55.3%)      1.21 (0.43--3.36)   0.716   8 (33.3%)    0.14 (0.07--0.31)   \<0.001    8 (7.8%)    0.81 (0.31--2.10)   0.67   8 (18.2%)

Abbreviations: CI=confidence interval; HPV=human papillomavirus; OR=odds ratio; Ref=reference value.

Adjusted for number of sexual partners, insurance, education, pack-years, alcohol, age, race, and gender.

[^1]: These authors contributed equally to this work.
